share_log

歌禮製藥-B：截至二零二四年三月三十一日止月份之股份發行人的證券變動月報表

ASCLETIS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 2 00:49
Summary by Moomoo AI
歌礼制药-B於2024年3月31日提交的最新證券變動月報表顯示，公司在2024年3月期間沒有增加或減少法定/註冊股本，維持在7,000,000,000股，每股面值0.0001美元，法定/註冊股本總額為700,000美元。報告亦提到，根據2019年6月6日通過的股份期權計劃，公司在3月份註銷了100,000股份期權，使得本月底結存的股份期權數目為11,306,841股。此外，歌礼制药-B在3月5日購回並註銷了32,063,000股普通股，這些股份是在2023年12月至2024年2月期間購回的。本月普通股的減少總額為32,063,000股。該變動已於2024年4月2日向香港交易及結算所有限公司報告。
歌礼制药-B於2024年3月31日提交的最新證券變動月報表顯示，公司在2024年3月期間沒有增加或減少法定/註冊股本，維持在7,000,000,000股，每股面值0.0001美元，法定/註冊股本總額為700,000美元。報告亦提到，根據2019年6月6日通過的股份期權計劃，公司在3月份註銷了100,000股份期權，使得本月底結存的股份期權數目為11,306,841股。此外，歌礼制药-B在3月5日購回並註銷了32,063,000股普通股，這些股份是在2023年12月至2024年2月期間購回的。本月普通股的減少總額為32,063,000股。該變動已於2024年4月2日向香港交易及結算所有限公司報告。
The company did not increase or decrease its regulated/registered share capital during March 2024 at 7,000,000,000 shares with a face value of $0.0001 per share and a total regulated/registered share capital of $700,000, according to the latest Securities Change Monthly Report filed on March 31, 2024. The report also noted that under the share option plan adopted on June 6, 2019, the company wrote off 100,000 share options in March, bringing the number of stock options outstanding at the end of the month to 11,306,841 shares. In addition, Charia Pharmaceutical-B repurchased and delisted 32,063,000 shares of ordinary shares on March 5, which were repurchased between December 2023 and February 2024. The total decrease in ordinary shares for the month was 32,063,000 shares. The change was reported to Hong Kong Trading and Settlement Limited on 2 April 2024.
The company did not increase or decrease its regulated/registered share capital during March 2024 at 7,000,000,000 shares with a face value of $0.0001 per share and a total regulated/registered share capital of $700,000, according to the latest Securities Change Monthly Report filed on March 31, 2024. The report also noted that under the share option plan adopted on June 6, 2019, the company wrote off 100,000 share options in March, bringing the number of stock options outstanding at the end of the month to 11,306,841 shares. In addition, Charia Pharmaceutical-B repurchased and delisted 32,063,000 shares of ordinary shares on March 5, which were repurchased between December 2023 and February 2024. The total decrease in ordinary shares for the month was 32,063,000 shares. The change was reported to Hong Kong Trading and Settlement Limited on 2 April 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more